ESF Forward Look on Personalised Medicine

513 views

Published on

European Science Foundation
www.esf.org
A Forward Look on Personalised Medicine
Stephane Berghmans
European Health Forum Gastein, 4-5 October 2012

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
513
On SlideShare
0
From Embeds
0
Number of Embeds
13
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ESF Forward Look on Personalised Medicine

  1. 1. www.esf.org A Forward Look on Personalised Medicine Stephane Berghmans1 European Health Forum Gastein, 4-5 October 2012 ESF Forward Look - EHFG, 4-5 October 2012
  2. 2. European Science Foundation Member Organisations ESF is an independent association of 78 Member Organisations • research funding organisations • research performing organisations • academies and learned societies in 30 countries2 ESF Forward Look - EHFG, 4-5 October 2012
  3. 3. Standing Committee domains •Biomedical Sciences •Humanities •Social Sciences •Life, Earth & Environmental Sciences •Physical and Engineering Sciences Expert Board/Committee domains •Marine Sciences • Radio Astronomy •Polar Sciences • Nuclear Physics •Space Sciences • Material Sciences & Engineering3 ESF Forward Look - EHFG, 4-5 October 2012
  4. 4. Forward Look on Personalised Medicine Foresight instrument ● Multidisciplinary topics or complex areas viewed at a European level ● Medium to long-term scientific perspectives ● Link scientists, stakeholders and policy makers ● Wide consultation – identify major opportunities and constraints ● Produce major reports and action plans4 ESF Forward Look - EHFG, 4-5 October 2012
  5. 5. ESF Forward Look on Personalised Medicine Governance Scientific Committee Management CommitteeChairs• Aarno Palotie, Head of Medical • Liselotte Højgaard EMRC, Chair Sequencing at the Wellcome Trust • Milena Zic-Fuchs SCH, Chair Sanger Institute, UK; Director of the Finnish Genome Center, University of • Michel Salzet LESC, member Helsinki , Finland • Rainer Kattel SCSS, core group member• Stephen Holgate, Medical Research • Jukka Corander PESC, representative Council, School of Medicine, University of Southampton, UK • Heyo K. Kroemer, DFG• Barbara Prainsack, Centre for Biomedicine & Society - CBAS Brunel, Deutsche Forschungsgemeinschaft UK • Jacques Grassi, Inserm Institut National de la Santé et de la• Angela Brand, IPHG, Faculty of Recherche Médicale Health, Medicine and Life Sciences, Maastricht University, The Netherlands • Joaquin Arenas Barbero, MICINN• Hans Lehrach, Max Planck Institute Spanish ministry for science and innovation for Molecular Genetics, Berlin, Germany 5 ESF Forward Look - EHFG, 4-5 October 2012
  6. 6. Forward Look on Personalised MedicineMethodology In -d in e p te th rv e ie xp w e s rt 6 ESF Forward Look - EHFG, 4-5 October 2012
  7. 7. Forward Look on Personalised Medicine TABLE OF CONTENT 1.Introduction 2.How do we define personalised medicine? 3.What can personalised medicine offer? 4.What are the technological considerations for personalised medicine? 5.What are the disciplinary considerations for personalised medicine? 6.What are the key issues affecting the development and implementation of personalised medicine? 7.Recommendations 8.Can we predict a timeline for the development and implementation of personalised medicine?7 ESF Forward Look - EHFG, 4-5 October 2012
  8. 8. Forward Look on Personalised Medicine TABLE OF CONTENT 1.Introduction 2.How do we define personalised medicine? 3.What can personalised medicine offer? 4.What are the technological considerations for personalised medicine? 5.What are the disciplinary considerations for personalised medicine? 6.What are the key issues affecting the development and implementation of personalised medicine? 7.Recommendations 8.Can we predict a timeline for the development and implementation of personalised medicine?8 ESF Forward Look - EHFG, 4-5 October 2012
  9. 9. Forward Look on Personalised Medicine 80 recommendations … resulting in a Personalised Medicine “Target”9 ESF Forward Look - EHFG, 4-5 October 2012
  10. 10. Forward Look on Personalised Medicine Personalised Medicine “Target” “At the heart of personalised medicine lies the individual citizen…”10 ESF Forward Look - EHFG, 4-5 October 2012
  11. 11. Forward Look on Personalised Medicine WHAT CAN PERSONALISED MEDICINE OFFER? For Personalised Medicine to be effectively introduced stakeholders must be clear about its benefitsTHE EUROPEAN CITIZEN•Promise of safer, more effective treatments Examples in stratified medicines to treat specific tumour subtypes•Longer-term promise: prevention of disease Genetic prediction Monitoring of physiological status over the life course•Empowerment: more control over their own health Today citizens don’t feel in control of decisions about their wellbeing Issues: less direct involvement of healthcare professionals health literacy and access 11 ESF Forward Look - EHFG, 4-5 October 2012
  12. 12. Forward Look on Personalised Medicine Personalised Medicine “Target” “… the citizen’s health status will be reflected by a new disease taxonomy informed by the multi-layered characterisation of physiological and pathological processes”12 ESF Forward Look - EHFG, 4-5 October 2012
  13. 13. Forward Look on Personalised Medicine WHAT CAN PERSONALISED MEDICINE OFFER?For Personalised Medicine to be effectively introduced stakeholders must be clear about its benefits FOR THE HEALTHCARE PROFESSION •Opportunities in diseases subclassification Possible greater insight into complex & chronic diseases More effective use of existing drugs Drug efficacy in unstratified patient groups •Potential for a life-course approach to healthcare Individual baseline physiological data Improved recognition of relevant pathological changes Opportunity for greater prevention; early intervention13 ESF Forward Look - EHFG, 4-5 October 2012
  14. 14. Forward Look on Personalised Medicine Personalised Medicine “Target” “Comprehensive, accessible, and interoperable datasets must be generated to support the development of a new disease taxonomy and allow for its ongoing refinement and application"14 ESF Forward Look - EHFG, 4-5 October 2012
  15. 15. Forward Look on Personalised MedicineWHAT ARE THE TECHNOLOGICAL CONSIDERATIONS FOR PM? Defining feature of PM will be data integration ICT ICT solutions solutions Global solutions 15 ESF Forward Look - EHFG, 4-5 October 2012
  16. 16. Forward Look on Personalised Medicine Personalised Medicine “Target” “Models and decision-making processes must be revised to reflect a focus on the individual citizen at all levels, from assessment of the safety and efficacy of interventions, through HTA and reimbursement, to diagnosis, treatment and prevention”16 ESF Forward Look - EHFG, 4-5 October 2012
  17. 17. Forward Look on Personalised Medicine WHAT CAN PERSONALISED MEDICINE OFFER? For Personalised Medicine to be effectively introduced stakeholders must be clear about its benefitsFOR REIMBURSEMENT BODIES•Will PM reduce health expenditure: promise or benchmark? e.g. investment in new technology and infrastructure e.g. drug reprofiling based on stratification Scepticism: PM has potential to increase healthcare expenditure•Cost of increased emphasis on diagnostics and preemptive testing? Direct cost of investment in diagnostics technology False-positive diagnosis (offset by long-term reductions through prevention?)•Realistic promise and expectations Cost containment vs. cost reduction: improved return on investment 17 ESF Forward Look - EHFG, 4-5 October 2012
  18. 18. Forward Look on Personalised Medicine Personalised Medicine “Target” “Emphasis must be placed on stakeholder participation, interdisciplinary interaction, public-private and precompetitive partnerships, and translational research in order to develop the frameworks that support the vision of personalised medicine and healthcare”18 ESF Forward Look - EHFG, 4-5 October 2012
  19. 19. Forward Look on Personalised MedicineWHAT ARE THE DISCIPLINARY CONSIDERATIONS FOR PM? THE CHALLENGE OF INTERDISCIPLINA RITY 3 disease areas Challenge Achieve cross-disciplinary consensus to allow PMchallenges to be addressed *approved by FDA as of September 2011 in each context 19 ESF Forward Look - EHFG, 4-5 October 2012
  20. 20. Forward Look on Personalised Medicine Personalised Medicine “Target” “Dedicated funding and governmental support must be provided to ensure the availability of core infrastructure, including access to core technology and frameworks for education and training of professionals and the wider community”20 ESF Forward Look - EHFG, 4-5 October 2012
  21. 21. Forward Look on Personalised Medicine Personalised Health Care Transformation Reform Change Management Stakeholder Engagement Critical Timing Proof of Principle ... Global Stakeholder Group21 ESF Forward Look - EHFG, 4-5 October 2012
  22. 22. Stephane Berghmans Formerly Currently Head of Unit CEO Biomedical Sciences Center for Innovation in Medicine European Science Foundation Liege, Belgium22 ESF Forward Look - EHFG, 4-5 October 2012

×